Literature DB >> 8301353

Toxicity of an antitumor ribonuclease to Purkinje neurons.

D L Newton1, S Walbridge, S M Mikulski, W Ardelt, K Shogen, S J Ackerman, S M Rybak, R J Youle.   

Abstract

Purkinje cell toxicity is one of the characteristic features of the Gordon phenomenon, a syndrome manifested by ataxia, muscular rigidity, paralysis, and tremor that may lead to death (Gordon, 1933). Two members of the RNase superfamily found in humans, EDN (eosinophil-derived neurotoxin) and ECP (eosinophil cationic protein), cause the Gordon phenomenon when injected intraventricularly into guinea pigs or rabbits. We have found that another member of the RNase superfamily, an antitumor protein called onconase, isolated from Rana pipiens oocytes and early embryos, will also cause the Gordon phenomenon when injected into the cerebrospinal fluid of guinea pigs at a dose similar to that of EDN (LD50, 3-4 micrograms). Neurologic abnormalities of onconase-treated animals were indistinguishable from those of EDN-treated animals, and histology showed dramatic Purkinje cell loss in the brains of onconase-treated animals. The neurotoxic activity of onconase correlates with ribonuclease activity. Onconase modified by iodoacetic acid to eliminate 70% and 98% of the ribonuclease activity of the native enzyme displays a similar decrease in ability to cause the Gordon phenomenon. In contrast, the homologous bovine pancreatic RNase A injected intraventricularly at a dose 5000 times greater than the LD50 dose of EDN or onconase is not toxic and does not cause the Gordon phenomenon. A comparison of the RNase activities of EDN, onconase, and bovine pancreatic RNase A using three pancreatic RNA substrates demonstrates that onconase is orders of magnitude less active enzymatically than EDN and RNase A. Thus, another member of the RNase superfamily in addition to EDN and ECP can cause the Gordon phenomenon.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301353      PMCID: PMC6576803     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  13 in total

1.  Diversity among the primate eosinophil-derived neurotoxin genes: a specific C-terminal sequence is necessary for enhanced ribonuclease activity.

Authors:  H F Rosenberg; K D Dyer
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

2.  Two highly homologous ribonuclease genes expressed in mouse eosinophils identify a larger subgroup of the mammalian ribonuclease superfamily.

Authors:  K A Larson; E V Olson; B J Madden; G J Gleich; N A Lee; J J Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis.

Authors:  Gail M Kephart; Jeffrey A Alexander; Amindra S Arora; Yvonne Romero; Thomas C Smyrk; Nicholas J Talley; Hirohito Kita
Journal:  Am J Gastroenterol       Date:  2009-11-03       Impact factor: 10.864

Review 4.  Eosinophils, ribonucleases and host defense: solving the puzzle.

Authors:  H F Rosenberg; J B Domachowske
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

5.  RNase inhibition of human immunodeficiency virus infection of H9 cells.

Authors:  R J Youle; Y N Wu; S M Mikulski; K Shogen; R S Hamilton; D Newton; G D'Alessio; M Gravell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

6.  Ribonuclease A variants with potent cytotoxic activity.

Authors:  P A Leland; L W Schultz; B M Kim; R T Raines
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 7.  Eosinophil-derived neurotoxin / RNase 2: connecting the past, the present and the future.

Authors:  H F Rosenberg
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

8.  Molecular cloning and characterization of a novel human ribonuclease (RNase k6): increasing diversity in the enlarging ribonuclease gene family.

Authors:  H F Rosenberg; K D Dyer
Journal:  Nucleic Acids Res       Date:  1996-09-15       Impact factor: 16.971

Review 9.  Rational immunotherapy with ribonuclease chimeras. An approach toward humanizing immunotoxins.

Authors:  S M Rybak; H R Hoogenboom; D L Newton; J C Raus; R J Youle
Journal:  Cell Biophys       Date:  1992 Aug-Dec

10.  The structural integrity exerted by N-terminal pyroglutamate is crucial for the cytotoxicity of frog ribonuclease from Rana pipiens.

Authors:  You-Di Liao; Sui-Chi Wang; Ying-Jen Leu; Chiu-Feng Wang; Shu-Ting Chang; Yu-Ting Hong; Yun-Ru Pan; Chinpan Chen
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.